Simvastatin Multiple Sclerosis

Simvastatin use as adjuvant thearapy in relapsing remitting multiple sclerosis

Simvastatin in relapsing remitting multiple sclerosis

Role of Simvastatin in Relapsing-Remitting Multiple Sclerosis

Double-blinded, Randomized Controlled Trial of Simvastatin Use As Adjuvant Therapy in Relapsing-Remitting Multiple Sclerosis

Time to confirmed disability progression between simvastatin and placebo arm based on change in EDSS scores compared to baseline

MSWS-12v2 is a12 item patient report measure on the impact of MS on the individual's walking ability over the previous 2 weeks. Each item will be summed to generate a total score and transformed to a scale with a range of 0 to 100 with high scores indicating greater impact on walking.

a quantitative mobility and leg function performance test based on a timed 25-foot walk

a brief, standardized, quantitative test of upper extremity function. Participants are instructed to pick up 9 pegs, one at a time, as quickly as possible and are required to insert them into 9 empty peg holes. Once all nine pegs have been inserted, the participant should immediately remove the pegs, one at a time. The total time taken to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The two trials for each hand are averaged.

is used to evaluate the degree of disability in daily activities of those with neurological disability

brief battery of six neuropsychological tasks designed to assess frontal lobe function. The six FAB tasks assess conceptualisation (abstract reasoning), item flexibility (verbal fluency), motor programming (organisation, maintenance and execution of successive actions), sensitivity to interference (conflicting instructions), inhibitory control (inhibit inappropriate responses), and environmental autonomy. The test takes approximately 10 minutes to complete.

Mena Mahfouz Fahim

researcher

Assiut University

DZ1 group receives DZ1 intratumoral injection in combination with radiation therapy.

Placebo group receives saline injection in combination with radiation therapy.

Nasopharyngeal Carcinoma

DZ1 in saline is administrated by intratumoral injection two hours prior to radiation therapy from week 1 to week 7 on Monday and Thursday. Dosage for each injection is 12 mg in 0.1 mL (200 micrograms per kilogram body weight.
The radical radiotherapy is given to patients 5 times per week with 2 Gy of each treatment. The entire procedure lasts seven weeks.

DNAzyme targeting EBV-LMP1 (DZ1)

0.1 mL of saline is administrated by intratumoral injection two hours prior to radiation therapy from week 1 to week 7 on Monday and Thursday.
The radical radiotherapy is given to patients 5 times per week with 2 Gy of each treatment. The entire procedure lasts seven weeks.

Saline

XiangYa Hospital, Central South University

Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma

Phase I/II Study of EBV-LMP1 Targeted DNAzyme in Nasopharyngeal Carcinoma

Tumor growth is measured using MRI weekly from week 1 to week 7, followed by six-monthly measures until week 104.

Tumor vasculature permeability is measured using DCE-MRI from week 1 to week 52. EBV DNA copies are measured monthly up to 24 months.EBV cpoies are measured by quantitative PCR.

Sun lunquan

Director, Center for Molecular Medicine, Central South University

Xiangya Hospital of Central South University

Parkinson Disease

Select Stim

University Hospital Maastricht

Select Stim: Selective Stimulation of the Subthalamic Nucleus in Parkinson's Disease. "A Feasibility Study"

Prof. Dr. Visser-Vandewalle

Maastricht University Medical Center

Participants will receive 80 mg of chloroquine on a daily basis.

Participants will receive a placebo comparator tablet on a daily basis.

Metabolic Syndrome X

Overweight

Hypertension

Dyslipidemias

Prediabetic State

One tablet of 80 mg of chloroquine on a daily basis for 12 months followed by 12 months off drug with 1 visit at month 24

Chloroquine

Chloroquine Placebo tablet daily for 12 months followed by 12 months off drug with 1 visit at month 24

Placebo Comparator

click here for Washington University Research Participant Registry

Washington University School of Medicine

Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS)

Genotoxic Stress, Atherosclerosis, and Metabolic Syndrome- Aim 3

A noninvasive predictor of cardiovascular events, Carotid artery intima-media thickness (CIMT) was measured from B-mode images by a single sonographer using standard approaches

ataxia/nekroz

Role of Simvastatin in Relapsing-Remitting Multiple Sclerosis

Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma

Select Stim: Selective Stimulation of the Subthalamic Nucleus in Parkinson's Disease. "A Feasibility Study"

Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS)

Bilim tarafından desteklenen en eksiksiz şifalı otlar veritabanı